Resultados de búsqueda - Jeffrey M. Besterman
- Mostrando 1 - 20 Resultados de 21
- Ir a la Siguiente Página
-
1
-
2
Endocytosis: a review of mechanisms and plasma membrane dynamics por Jeffrey M. Besterman, R B Low
Publicado 1983Revisão -
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. por N Sahyoun, Marlene Wolf, Jeffrey M. Besterman, Tsung‐Cheng Hsieh, M Sander, Harry LeVine, Kwen‐Jen Chang, Pedro Cuatrecasas
Publicado 1986Artigo -
13
Mammalian DNA Ligase III: Molecular Cloning, Chromosomal Localization, and Expression in Spermatocytes Undergoing Meiotic Recombination por Jingwen Chen, Alan E. Tomkinson, William Ramos, Zachary B. Mackey, Sue Danehower, Christi A. Walter, Roger A. Schultz, Jeffrey M. Besterman, Intisar Husain
Publicado 1995Artigo -
14
The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism por Daniela Buglio, Vidya Mamidipudi, Noor M. Khaskhely, Helen Brady, Carla Heise, Jeffrey M. Besterman, Robert E. Martell, Kyle J. MacBeth, Anas Younes
Publicado 2010Artigo -
15
Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay por Claire Bonfils, Ann Kalita, Marja Dubay, Lillian L. Siu, Michael A. Carducci, Gregory K. Reid, Robert E. Martell, Jeffrey M. Besterman, Zuomei Li
Publicado 2008Artigo -
16
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly por David J. Stewart, Ross C. Donehower, Elizabeth A. Eisenhauer, Nancy Wainman, Ajit Shah, Claire Bonfils, A. Robert MacLeod, Jeffrey M. Besterman, Gregory K. Reid
Publicado 2003Artigo -
17
Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors por Lillian L. Siu, Роберто Пили, Ignacio Durán, Wells A. Messersmith, Eric X. Chen, Rana Sullivan, Martha MacLean, Serina King, Shirley Brown, Gregory K. Reid, Zuomei Li, Ann Kalita, Eric Laille, Jeffrey M. Besterman, Robert E. Martell, Michael A. Carducci
Publicado 2008Artigo -
18
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial por Anas Younes, Yasuhiro Oki, R. Gregory Bociek, John Kuruvilla, Michelle A. Fanale, Sattva S. Neelapu, Amanda Copeland, Daniela Buglio, Ahmed Galal, Jeffrey M. Besterman, Zuomei Li, Michel Drouin, Tracy Patterson, M. Renee Ward, Jessica K. Paulus, Yuan Ji, L. Jeffrey Medeiros, Robert E. Martell
Publicado 2011Artigo -
19
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia por Guillermo Garcia‐Manero, Sarit Assouline, Jorge E. Cortés, Zeev Estrov, Hagop M. Kantarjian, Hui Yang, Willie Newsome, Wilson H. Miller, Caroline Rousseau, Ann Kalita, Claire Bonfils, Marja Dubay, T. Patterson, Zuomei Li, Jeffrey M. Besterman, Gregory K. Reid, Eric Laille, Robert E. Martell, Mark D. Minden
Publicado 2008Artigo -
20
Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors por Ruth Plummer, Laura Vidal, Martin Griffin, Mark Lesley, Johann S. de Bono, Sally A. Coulthard, Julieann Sludden, Lillian L. Siu, Eric X. Chen, Amit M. Oza, Gregory K. Reid, A. Robert McLeod, Jeffrey M. Besterman, Chooi Lee, Ian Judson, Hilary Calvert, Alan V. Boddy
Publicado 2009Artigo
Herramientas de búsqueda:
Materias Relacionadas
Biochemistry
Biology
Chemistry
Gene
Medicine
Internal medicine
Molecular biology
Pharmacology
Cancer research
Histone
Histone deacetylase
In vitro
Membrane
Pharmacokinetics
Protein kinase C
Biotechnology
Gastroenterology
Genetics
Histone deacetylase inhibitor
In vivo
Pharmacodynamics
Adverse effect
Amiloride
Endocrinology
Enzyme
Intracellular
Methylation
Methyltransferase
Nausea
Organic chemistry